{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:21:06Z","timestamp":1777497666118,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003407","name":"MIUR","doi-asserted-by":"crossref","award":["PRIN 2017Z3N3YC"],"award-info":[{"award-number":["PRIN 2017Z3N3YC"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019852","name":"Dipartimento di Scienze Chimiche e Farmaceutiche, Universit\u00e0 degli Studi di Ferrara","doi-asserted-by":"publisher","award":["FAR 2021"],"award-info":[{"award-number":["FAR 2021"]}],"id":[{"id":"10.13039\/501100019852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007109","name":"Universit\u00e0 degli Studi di Ferrara","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Clinical control of corticotroph tumors is difficult to achieve since they usually persist or relapse after surgery. Pasireotide is approved to treat patients with Cushing\u2019s disease for whom surgical therapy is not an option. However, Pasireotide seems to be effective only in a sub-set of patients, highlighting the importance to find a response marker to this approach. Recent studies demonstrated that the delta isoform of protein kinase C (PRKCD) controls viability and cell cycle progression of an in vitro model of ACTH-secreting pituitary tumor, the AtT-20\/D16v-F2 cells. This study aims at exploring the possible PRKCD role in mediating Pasireotide effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>It was assessed cell viability, POMC expression and ACTH secretion in AtT20\/D16v-F2 cells over- or under-expressing PRKCD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that Pasireotide significantly reduces AtT20\/D16v-F2 cell viability, POMC expression and ACTH secretion. In addition, Pasireotide reduces miR-26a expression. PRKCD silencing decreases AtT20\/D16v-F2 cell sensitivity to Pasireotide treatment; on the contrary, PRKCD overexpression increases the inhibitory effects of Pasireotide on cell viability and ACTH secretion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results provide new insights into potential PRKCD contribution in Pasireotide mechanism of action and suggest that PRKCD might be a possible marker of therapeutic response in ACTH-secreting pituitary tumors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-023-02117-0","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T06:02:11Z","timestamp":1685080931000},"page":"2609-2616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line"],"prefix":"10.1007","volume":"46","author":[{"given":"E.","family":"Gentilin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Borges De Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bondanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Gagliardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8408-7796","authenticated-orcid":false,"given":"M. C.","family":"Zatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"2117_CR1","doi-asserted-by":"publisher","first-page":"1060884","DOI":"10.3389\/fendo.2022.1060884","volume":"13","author":"A Gilis-Januszewska","year":"2022","unstructured":"Gilis-Januszewska A, Bogus\u0142awska A, Rzepka E, Ziaja W, Hubalewska-Dydejczyk A (2022) Individualized medical treatment options in Cushing disease. Front Endocrinol (Lausanne) 13:1060884. https:\/\/doi.org\/10.3389\/fendo.2022.1060884","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2117_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.wneu.2023.01.108","volume":"172","author":"M Sabahi","year":"2023","unstructured":"Sabahi M, Ghasemi-Nesari P, Maroufi SF, Shahbazi T, Yousefi O, Shahtaheri SA, Bin-Alamer O, Dabecco R, Velasquez N, Arce KM, Adada B, Benjamin CG, Borghei-Razavi H (2023) Recurrent cushing disease: an extensive review on pros and cons of different therapeutic approaches. World Neurosurg 172:49\u201365. https:\/\/doi.org\/10.1016\/j.wneu.2023.01.108","journal-title":"World Neurosurg"},{"key":"2117_CR3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11154-022-09710-3","volume":"23","author":"M Bolanowski","year":"2022","unstructured":"Bolanowski M, Ka\u0142u\u017cny M, Witek P, Jawiarczyk-Przyby\u0142owska A (2022) Pasireotide-a novel somatostatin receptor ligand after 20 years of use. Rev Endocr Metab Disord 23:601\u2013620. https:\/\/doi.org\/10.1007\/s11154-022-09710-3","journal-title":"Rev Endocr Metab Disord"},{"key":"2117_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11102-019-01021-2","volume":"23","author":"A Lacroix","year":"2020","unstructured":"Lacroix A, Gu F, Schopohl J, Kandra A, Pedroncelli AM, Jin L, Pivonello R (2020) Pasireotide treatment significantly reduces tumor volume in patients with Cushing\u201ds disease: results from a Phase 3 study. Pituitary 23:203\u2013211. https:\/\/doi.org\/10.1007\/s11102-019-01021-2","journal-title":"Pituitary"},{"key":"2117_CR5","doi-asserted-by":"publisher","first-page":"650791","DOI":"10.3389\/fendo.2021.650791","volume":"12","author":"M Yamamoto","year":"2021","unstructured":"Yamamoto M, Nakao T, Ogawa W, Fukuoka H (2021) Aggressive Cushing\u2019s disease: molecular pathology and its therapeutic approach. Front Endocrinol (Lausanne). 12:650791. https:\/\/doi.org\/10.3389\/fendo.2021.650791","journal-title":"Front Endocrinol (Lausanne)."},{"key":"2117_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.mce.2015.10.025","volume":"419","author":"E Gentilin","year":"2016","unstructured":"Gentilin E, Di Pasquale C, Gagliano T, Tagliati F, Benfini K, Ambrosio MR, Bondanelli M, degli Uberti EC, Zatelli MC, (2016) Protein kinase C delta restrains growth in ACTH-secreting pituitary adenoma cells. Mol Cell Endocrinol 419:252\u2013258. https:\/\/doi.org\/10.1016\/j.mce.2015.10.025","journal-title":"Mol Cell Endocrinol"},{"key":"2117_CR7","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1210\/jc.2006-1245","volume":"91","author":"DL Batista","year":"2006","unstructured":"Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A (2006) The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91:4482\u20134488. https:\/\/doi.org\/10.1210\/jc.2006-1245","journal-title":"J Clin Endocrinol Metab"},{"key":"2117_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.reprotox.2014.01.008","volume":"45","author":"E Gentilin","year":"2014","unstructured":"Gentilin E, Mol\u00e8 D, Gagliano T, Minoia M, Ambrosio MR, Degli Uberti EC, Zatelli MC (2014) Inhibitory effects of mitotane on viability and secretory activity in mouse gonadotroph cell lines. Reprod Toxicol 45:71\u201376. https:\/\/doi.org\/10.1016\/j.reprotox.2014.01.008","journal-title":"Reprod Toxicol"},{"key":"2117_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1530\/JOE-13-0210","volume":"218","author":"E Gentilin","year":"2013","unstructured":"Gentilin E, Tagliati F, Terzolo M, Zoli M, Lapparelli M, Minoia M, Ambrosio MR, Degli Uberti EC, Zatelli MC (2013) Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function. J Endocrinol 218:275\u2013285. https:\/\/doi.org\/10.1530\/JOE-13-0210","journal-title":"J Endocrinol"},{"key":"2117_CR10","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1210\/en.2012-2070","volume":"154","author":"E Gentilin","year":"2013","unstructured":"Gentilin E, Tagliati F, Filieri C, Mol\u00e8 D, Minoia M, Ambrosio MR, Degli Uberti EC, Zatelli MC (2013) miR-26a plays an important role in cell cycle regulation in ACTH-secreting pituitary adenomas by modulating protein kinase C\u03b4. Endocrinology 154:1690\u20131700. https:\/\/doi.org\/10.1210\/en.2012-2070","journal-title":"Endocrinology"},{"key":"2117_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1210\/jc.2018-02080","volume":"104","author":"M Theodoropoulou","year":"2019","unstructured":"Theodoropoulou M, Reincke M (2019) Tumor-directed therapeutic targets in cushing disease. J Clin Endocrinol Metab 104:925\u2013933. https:\/\/doi.org\/10.1210\/jc.2018-02080","journal-title":"J Clin Endocrinol Metab"},{"key":"2117_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1210\/jc.2008-1008","volume":"94","author":"M Boscaro","year":"2009","unstructured":"Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BMKK, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J (2009) Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94:115\u2013122. https:\/\/doi.org\/10.1210\/jc.2008-1008","journal-title":"J Clin Endocrinol Metab"},{"key":"2117_CR13","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJMc1000094","volume":"362","author":"RA Feelders","year":"2010","unstructured":"Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ, de Herder WW, Hofland LJ, Lamberts SW (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease. N Engl J Med 362:1846\u20131848. https:\/\/doi.org\/10.1056\/NEJMc1000094","journal-title":"N Engl J Med"},{"key":"2117_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM (2012) Pasireotide B2305 study group. A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366:914\u2013924. https:\/\/doi.org\/10.1056\/NEJMoa1105743","journal-title":"N Engl J Med"},{"key":"2117_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s11102-013-0503-3","volume":"17","author":"M Boscaro","year":"2014","unstructured":"Boscaro M, Bertherat J, Findling J, Fleseriu M, Atkinson AB, Petersenn S, Schopohl J, Snyder P, Hughes G, Trovato A, Hu K, Maldonado M, Biller BMK (2014) Extended treatment of Cushing\u2019s disease with pasireotide: results from a 2-year, phase II study. Pituitary 17:320\u2013326. https:\/\/doi.org\/10.1007\/s11102-013-0503-3","journal-title":"Pituitary"},{"key":"2117_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s11102-014-0618-1","volume":"18","author":"J Schopohl","year":"2015","unstructured":"Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J, Ligueros-Saylan M, Trovato A, Hughes G, Salgado LR, Boscaro M, Pivonello R (2015) Pasireotide B2305 Study Group. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing\u2019s disease: results from an openended, open-label extension trial. Pituitary 18:604\u2013612. https:\/\/doi.org\/10.1007\/s11102-014-0618-1","journal-title":"Pituitary"},{"key":"2117_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","volume":"6","author":"A Lacroix","year":"2018","unstructured":"Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, Boscaro M, Salvatori R, Yamada M, Tauchmanova L, Roughton M, Ravichandran S, Petersenn S, Biller BMK, Newell-Price J (2018) Pasireotide G2304 Study Group. Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol 6:17\u201326. https:\/\/doi.org\/10.1016\/S2213-8587(17)30326-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2117_CR18","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1055\/a-1158-9214.E","volume":"29","author":"SM Fill","year":"2021","unstructured":"Fill SM, Popp KH, Stalla GK, Athanasoulia-Kaspar AP (2021) Exceptional response of nelson\u2019s syndrome to Pasireotide LAR in the long-term follow-up of 9\u00a0years. Exp Clin Endocrinol Diabetes 29:776\u2013778. https:\/\/doi.org\/10.1055\/a-1158-9214.E","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2117_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40842-020-00110-7","volume":"6","author":"X He","year":"2020","unstructured":"He X, Spencer-Segal JL (2020) Rapid response of Nelson\u2019s syndrome to pasireotide in radiotherapy-naive patient. Clin Diabetes Endocrinol 6:22. https:\/\/doi.org\/10.1186\/s40842-020-00110-7","journal-title":"Clin Diabetes Endocrinol"},{"key":"2117_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000327429","volume":"94","author":"V Castillo","year":"2011","unstructured":"Castillo V, Theodoropoulou M, Stalla J, Gallelli MF, Cabrera Blatter MF, Haedo MR, Labeur M, Schmid HA, Stalla K, Arzt E (2011) Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing\u2019s disease. Neuroendocrinol 94:124\u2013136. https:\/\/doi.org\/10.1159\/000327429","journal-title":"Neuroendocrinol"},{"key":"2117_CR21","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1530\/eje.1.01998","volume":"153","author":"AP Silva","year":"2005","unstructured":"Silva AP, Schoeffter P, Weckbecker G, Bruns C, Schmid HA (2005) Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur J Endocrinol 153:R7\u2013R10. https:\/\/doi.org\/10.1530\/eje.1.01998","journal-title":"Eur J Endocrinol"},{"key":"2117_CR22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1530\/eje.1.01876","volume":"152","author":"LJ Hofland","year":"2005","unstructured":"Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SWJ (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152:645\u2013654. https:\/\/doi.org\/10.1530\/eje.1.01876","journal-title":"Eur J Endocrinol"},{"key":"2117_CR23","doi-asserted-by":"publisher","first-page":"E278","DOI":"10.1152\/ajpendo.00004.2005","volume":"289","author":"J van der Hoek","year":"2005","unstructured":"van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SWJ, Hofland LJ (2005) Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 289:E278\u2013E287. https:\/\/doi.org\/10.1152\/ajpendo.00004.2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2117_CR24","doi-asserted-by":"publisher","first-page":"935759","DOI":"10.3389\/fendo.2022.935759","volume":"13","author":"A Mondin","year":"2022","unstructured":"Mondin A, Manara R, Voltan G, Tizianel I, Denaro L, Ferrari M, Barbot M, Scaroni C, Ceccato F (2022) Pasireotide-induced shrinkage in GH and ACTH secreting pituitary adenoma: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 13:935759. https:\/\/doi.org\/10.3389\/fendo.2022.935759","journal-title":"Front Endocrinol (Lausanne)."},{"key":"2117_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s11306-022-01949-w","volume":"8","author":"DT Loots","year":"2022","unstructured":"Loots DT, Adeniji AA, Van Reenen M, Ozturk M, Brombacher F, Parihar SP (2022) The metabolomics of a protein kinase C delta (PKC\u03b4) knock-out mouse model. Metabolomics 8:92. https:\/\/doi.org\/10.1007\/s11306-022-01949-w","journal-title":"Metabolomics"},{"key":"2117_CR26","doi-asserted-by":"publisher","first-page":"109374","DOI":"10.1016\/j.intimp.2022.109374","volume":"113","author":"S Li","year":"2022","unstructured":"Li S, Huang Q, Zhou D, He B (2022) PRKCD as a potential therapeutic target for chronic obstructive pulmonary disease. Int Immunopharmacol 113:109374. https:\/\/doi.org\/10.1016\/j.intimp.2022.109374","journal-title":"Int Immunopharmacol"},{"key":"2117_CR27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1006\/bbrc.2001.5199","volume":"285","author":"A Stet\u00e1k","year":"2001","unstructured":"Stet\u00e1k A, Lankenau A, V\u00e1ntus T, Csermely P, Ullrich A, K\u00e9ri G (2001) The antitumor somatostatin analogue TT-232 induces cell cycle arrest through PKCdelta and c-Src. Biochem Biophys Res Commun 285:483\u2013488. https:\/\/doi.org\/10.1006\/bbrc.2001.5199","journal-title":"Biochem Biophys Res Commun"},{"key":"2117_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000314296","volume":"92","author":"LJ Hofland","year":"2010","unstructured":"Hofland LJ, Lamberts SW, Feelders RA (2010) Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells. Neuroendocrinol 92:11\u201316. https:\/\/doi.org\/10.1159\/000314296","journal-title":"Neuroendocrinol"},{"key":"2117_CR29","doi-asserted-by":"publisher","first-page":"E1880","DOI":"10.1210\/jc.2013-1987","volume":"98","author":"R Van der Pas","year":"2013","unstructured":"Van der Pas R, Feelders RA, Gatto F, de Bruin C, Pereira AM, van Koetsveld PM, Sprij-Mooij DM, Waaijers AM, Dogan F, Schulz S, Kros JM, Lamberts SW, Hofland LJ (2013) Preoperative normalization of cortisol levels in Cushing\u2019s disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists. J Clin Endocrinol Metab 98:E1880\u2013E1890. https:\/\/doi.org\/10.1210\/jc.2013-1987","journal-title":"J Clin Endocrinol Metab"},{"key":"2117_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1530\/JOE-16-0332","volume":"231","author":"A Ib\u00e1\u00f1ez-Costa","year":"2016","unstructured":"Ib\u00e1\u00f1ez-Costa A, Rivero-Cort\u00e9s E, V\u00e1zquez-Borrego MC, Gahete MD, Jim\u00e9nez-Reina L, Venegas-Moreno E, de la Riva A, Arr\u00e1ez M\u00c1, Gonz\u00e1lez-Molero I, Schmid HA, Maraver-Selfa S, Gavil\u00e1n-Villarejo I, Garc\u00eda-Arn\u00e9s JA, Jap\u00f3n MA, Soto-Moreno A, G\u00e1lvez MA, Luque RM, Casta\u00f1o JP (2016) Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro. J Endocrinol 231:135\u2013145. https:\/\/doi.org\/10.1530\/JOE-16-0332","journal-title":"J Endocrinol"},{"key":"2117_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mce.2014.07.001","volume":"394","author":"S Murasawa","year":"2014","unstructured":"Murasawa S, Kageyama K, Sugiyama A, Ishigame N, Niioka K, Suda T, Daimon M (2014) Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo. Mol Cell Endocrinol 394:37\u201346. https:\/\/doi.org\/10.1016\/j.mce.2014.07.001","journal-title":"Mol Cell Endocrinol"},{"key":"2117_CR32","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S0021-9258(17)42285-X","volume":"269","author":"YC Patel","year":"1994","unstructured":"Patel YC, Panetta R, Escher E, Greenwood M, Srikant CB (1994) Expression of multiple somatostatin receptor genes in AtT-20 cells. Evidence for a novel somatostatin-28 selective receptor subtype. J Biol Chem 269:1506\u20131509","journal-title":"J Biol Chem"},{"key":"2117_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.mrrev.2017.05.002","volume":"773","author":"AA Stepanenko","year":"2017","unstructured":"Stepanenko AA, Heng HH (2017) Transient and stable vector transfection: pitfalls, off-target effects, artifacts. Mutat Res Rev Mutat Res 773:91\u2013103. https:\/\/doi.org\/10.1016\/j.mrrev.2017.05.002","journal-title":"Mutat Res Rev Mutat Res"},{"key":"2117_CR34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1530\/EC-20-0035","volume":"9","author":"S Castellnou","year":"2020","unstructured":"Castellnou S, Vasiljevic A, Lapras V, Raverot V, Alix E, Borson-Chazot F, Jouanneau E, Raverot G, Lasolle H (2020) SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors. Endocr Connect 9:243\u2013253. https:\/\/doi.org\/10.1530\/EC-20-0035","journal-title":"Endocr Connect"},{"key":"2117_CR35","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-22-0088","author":"A Albani","year":"2022","unstructured":"Albani A, Perez-Rivas LG, Tang S, Simon J, Lucia KE, Col\u00f3n Bolea P, Schopohl J, Roeber S, Buchfelder M, Rotermund R, Flitsch J, Thorsteinsdottir J, Herms J, Stalla G, Reincke M, Theodoropoulou M (2022) Improved pasireotide response in USP8 mutant corticotroph tumours in vitro. Endocr Relat Cancer. https:\/\/doi.org\/10.1530\/ERC-22-0088","journal-title":"Endocr Relat Cancer"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02117-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02117-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02117-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T17:22:48Z","timestamp":1699464168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02117-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2117"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02117-0","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the Authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}